Cost-Effectiveness of AI-Powered Decentralized Production for Advanced Therapies in the Hospital–Generated Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma From a German Hospital Perspective: Early Health Technology Assessment Study
JMIR Cancer · 2026
DOI: 10.2196/92253 ↗Kurz gefasst
Fachartikel in der Zeitschrift JMIR Cancer, 2026. Verfasst von Iris W A Boot und 3 weiteren Autor:innen. Beteiligte Einrichtung: Panaxea, 's-Hertogenbosch, The Netherlands. Hauptthemen laut MEDLINE: Multiple Myeloma, Technology Assessment, Biomedical, Immunotherapy, Adoptive, Receptors, Chimeric Antigen. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Although effective, current chimeric antigen receptor T-cell (CAR-T) production methods—centralized, manual, and complex—are cost-intensive, time-consuming, and prone to variability. AIDPATH (AI-Powered Decentralized Production for Advanced Therapies in the Hospital) proposes a decentralized, automated alternative that integrates patient-specific data; optimizes resource use; and potentially improves cell viability, manufacturing efficiency, and patient outcomes.
Objective
The aim of this study was to compare CAR-T therapy produced by the AIDPATH platform to both ciltacabtagene autoleucel (cilta-cel) and standard of care (SoC) for patients with triple-class refractory multiple myeloma (MM) over a 40-year time horizon from the hospital perspective in Germany.
Methods
A partitioned survival model reflecting 3 health states (progression-free disease, progressed disease, and death) was used. The analysis used clinical trial data for cilta-cel, real-world data for SoC, and estimated parameters for AIDPATH due to the developmental status of the platform. The primary outcome was the incremental cost-effectiveness ratio; secondary outcomes included sensitivity and scenario analyses.
Results
On the basis of the model used in this analysis, AIDPATH was dominant compared to both cilta-cel and SoC. Most costs for CAR-T therapies were driven by acquisition and adverse events. Sensitivity analyses showed that the results were most influenced by discount rates and assumptions about progression-free survival. Scenario analyses, including reduced adverse events and shorter vein-to-vein times for AIDPATH, further supported its cost-effectiveness.
Conclusions
This is the first study to assess the cost-effectiveness of a CAR-T product generated with AI support in Germany from the hospital perspective. AIDPATH was found to be a cost-effective alternative to both cilta-cel and SoC, making it a promising option for future implementation. Although further data are needed, this study provides valuable guidance for health care stakeholders, reimbursement discussions, and future research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Panaxea, 's-Hertogenbosch, The Netherlands.
- Department Bio-adaptive Production, Fraunhofer Institute for Production Technology IPT, Aachen, North Rhine-Westphalia, Germany.
- Faculty of Health, Medicine and Life Sciences, Maastricht University, Maatricht, Limburg, The Netherlands.
ORCID-Profile: Iris W A Boot, Anna Louisa Weltin, Ysanne de Graaf, Hubertus J M Vrijhoef
Zitieren
APA
Boot, I. W. A., Weltin, A. L., de Graaf, Y., & Vrijhoef, H. J. M. (2026). Cost-Effectiveness of AI-Powered Decentralized Production for Advanced Therapies in the Hospital–Generated Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma From a German Hospital Perspective: Early Health Technology Assessment Study. JMIR Cancer. https://doi.org/10.2196/92253
Vancouver
Boot IWA, Weltin AL, de Graaf Y, Vrijhoef HJM. Cost-Effectiveness of AI-Powered Decentralized Production for Advanced Therapies in the Hospital–Generated Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma From a German Hospital Perspective: Early Health Technology Assessment Study. JMIR Cancer. 2026. doi:10.2196/92253
BibTeX
@article{Boot2026,
author = {Boot, Iris W A and Weltin, Anna Louisa and de Graaf, Ysanne and Vrijhoef, Hubertus J M},
title = {Cost-Effectiveness of AI-Powered Decentralized Production for Advanced Therapies in the Hospital–Generated Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma From a German Hospital Perspective: Early Health Technology Assessment Study},
journal = {JMIR Cancer},
year = {2026},
doi = {10.2196/92253}
}
EUVIMED